Literature DB >> 4000066

Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination.

C Kraus, S Fischer, R Ansorg, U Hüttemann.   

Abstract

An enzyme-linked immunoassay was used to determine serum content of IgG and IgM antibodies against eight capsular polysaccharides of Streptococcus pneumoniae in 19 patients with chronic obstructive lung diseases 3 years after inoculation with a polyvalent pneumococcal vaccine (Moniatrix); 21 unvaccinated patients with comparable diseases served as the control group. The vaccinated group showed slightly more pronounced IgG antibody reactions than the unvaccinated group, but the differences were not statistically significant. These results show that pneumococcal vaccination does not provide long-term protection at least for patients with chronic obstructive lung disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4000066     DOI: 10.1007/bf02123671

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  12 in total

1.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

2.  Studies in human subjects of polyvalent pneumococcal vaccines (39894).

Authors:  R E Weibel; P P Vella; A A McLean; A F Woodhour; W L Davidson; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1977-10

Review 3.  Lung defense mechanisms (second of two parts).

Authors:  M Newhouse; J Sanchis; J Bienenstock
Journal:  N Engl J Med       Date:  1976-11-04       Impact factor: 91.245

4.  Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine.

Authors:  M A Mufson; H E Krause; G Schiffman
Journal:  Proc Soc Exp Biol Med       Date:  1983-06

5.  Persistence of Pneumococcal antibodies in human subjects following vaccination.

Authors:  P P Vella; A A McLean; A F Woodhour; R E Weibel; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1980-09

6.  The assessment of pneumococcal vaccine.

Authors:  R Austrian
Journal:  N Engl J Med       Date:  1980-09-04       Impact factor: 91.245

7.  Serological diagnosis of pneumococcal disease with enzyme-linked immunosorbent assay (ELISA).

Authors:  E Berntsson; K A Broholm; B Kaijser
Journal:  Scand J Infect Dis       Date:  1978

8.  Quantitation of T-lymphocyte subsets in human bronchus mucosa.

Authors:  A Puci; R Clancy; G Jackson
Journal:  Am Rev Respir Dis       Date:  1982-08

9.  Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine.

Authors:  C V Broome; R R Facklam; D W Fraser
Journal:  N Engl J Med       Date:  1980-09-04       Impact factor: 91.245

10.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.

Authors:  C M Macleod; R G Hodges; M Heidelberger; W G Bernhard
Journal:  J Exp Med       Date:  1945-11-30       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  A cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients.

Authors:  C A Marra; D M Patrick; F Marra
Journal:  Can J Public Health       Date:  2000 Sep-Oct

Review 3.  Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.

Authors:  Julia Ae Walters; Joanne Ngie Qing Tang; Phillippa Poole; Richard Wood-Baker
Journal:  Cochrane Database Syst Rev       Date:  2017-01-24

Review 4.  Toward targeting inflammasomes: insights into their regulation and activation.

Authors:  Shelbi Christgen; David E Place; Thirumala-Devi Kanneganti
Journal:  Cell Res       Date:  2020-03-09       Impact factor: 25.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.